Key Details
Price
$3.50Annual ROE
-39.02%Beta
1.81Events Calendar
Next earnings date:
Mar 18, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 18, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call.
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode.
The artificial intelligence ( AI ) boom is far from over. For example let's look at Nvidia (NASDAQ: NVDA ), where CEO Jensen Huang still believes his stock is wildly undervalued.
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margave – Chief Financial Officer Conference Call Participants Nicole Leber Good afternoon, everyone. I'm Nicole Leber with Investor Relations here at Lantern Pharma.
As we forge ahead into the AI era, the top AI penny stocks have become increasingly relevant, emerging as a buzzword among savvy investors. Projected to inject a massive $15.7 trillion into the global economy by the conclusion of the current decade, AI is no longer just the playground for large-cap tech giants.
The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trillion opportunity by 2030, says Grand View Research.
AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but their long-term growth prospects are enticing.
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma.
FAQ
- What is the primary business of Lantern Pharma?
- What is the ticker symbol for Lantern Pharma?
- Does Lantern Pharma pay dividends?
- What sector is Lantern Pharma in?
- What industry is Lantern Pharma in?
- What country is Lantern Pharma based in?
- When did Lantern Pharma go public?
- Is Lantern Pharma in the S&P 500?
- Is Lantern Pharma in the NASDAQ 100?
- Is Lantern Pharma in the Dow Jones?
- When was Lantern Pharma's last earnings report?
- When does Lantern Pharma report earnings?
- Should I buy Lantern Pharma stock now?